Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease
Status:
Active, not recruiting
Trial end date:
2022-02-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to monitor ongoing safety in subjects with ulcerative colitis
(UC) and Crohn's disease (CD) and to provide access to vedolizumab for qualifying subjects
who, in the opinion of the investigator, continue to derive benefit from vedolizumab and for
whom continued treatment with vedolizumab is desired because there is no other comparable
product available or the subject may be expected to develop worsening of disease if they were
to modify treatment.